Corrective Actions "Inadequate," U.S. FDA Warns Ranbaxy; Threatens Seizure And Injunction
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Ranbaxy's four-year-long tangle with U.S. FDA over the Indian firm's troubled manufacturing sites took one more serious turn as the world's most powerful regulatory agency fired another salvo saying: "It is apparent that Ranbaxy's attempts to make global corrections after past regulatory actions by the FDA have been inadequate.
You may also be interested in...
Ranbaxy Shutters Liquids Unit At Gloversville Citing Rationalization; Keeps Optimism On Lipitor Exclusivity
MUMBAI - Calling it a process of rationalization, Ranbaxy Laboratories Ltd. announced that it has shut down the liquids manufacturing facility at its U.S.-based Ohm Labs unit based in Gloversville, New York. Ranbaxy Managing Director Arun Sawhney told analysts and investors during an Aug. 5 conference call to detail second quarter earnings that the company continuously looks at its global plants to maximize efficiencies. In the past, Ranbaxy has eased out from manufacturing operations in China and Vietnam
Ranbaxy Shutters Liquids Unit At Gloversville Citing Rationalization; Keeps Optimism On Lipitor Exclusivity
MUMBAI - Calling it a process of rationalization, Ranbaxy Laboratories Ltd. announced that it has shut down the liquids manufacturing facility at its U.S.-based Ohm Labs unit based in Gloversville, New York. Ranbaxy Managing Director Arun Sawhney told analysts and investors during an Aug. 5 conference call to detail second quarter earnings that the company continuously looks at its global plants to maximize efficiencies. In the past, Ranbaxy has eased out from manufacturing operations in China and Vietnam
Ranbaxy Shutters New York Liquids Unit Citing Rationalization, Keeps Optimism On Lipitor Exclusivity
The unit, part of the larger Ohm Labs facility, was the focus of an FDA warning to Ranbaxy last year to undertake comprehensive assessment of all its manufacturing sites for GMP compliance.